比较新辅助放化疗后开放与胸腔镜食管切除术治疗食管鳞状细胞癌患者的生存
本研究基于台湾癌症登记库2008至2016年数据,纳入2250例接受新辅助放化疗的食管鳞状细胞癌患者,比较开放(n=487)与胸腔镜(n=1763)食管切除术的总生存。倾向评分匹配后开放组353例、胸腔镜组706例,3年总生存率相似(39.18% vs 44.33%,p=0.11);在y-pCR、y-pIII及y-pT0N+亚组中胸腔镜组生存更优。
要点
- 匹配后开放与胸腔镜食管切除术3年总生存率相似(39.18% vs 44.33%,p=0.11)。
- y-pCR患者胸腔镜组3年生存率高于开放组(57.26% vs 65.19%,p=0.045)。
- y-pIII及y-pT0N+患者胸腔镜组生存优于开放组(p=0.028、p=0.010)。
核心结论
- 倾向评分匹配研究显示,在接受新辅助放化疗的食管鳞状细胞癌患者中,开放与胸腔镜食管切除术的长期生存相似。
- 亚组比较显示,胸腔镜食管切除术在病理完全缓解、y-pIII及y-pT0N+期患者中生存优于开放手术,在y-pI/II期患者中生存相似。
研究设计与样本
- 查询2008至2016年台湾癌症登记库,纳入2250例接受新辅助放化疗的食管鳞状细胞癌患者。
- 患者接受开放(n=487)或胸腔镜(n=1763)食管切除术,并进行开放与胸腔镜一比二倾向评分匹配。
- 匹配后开放组353例,胸腔镜组706例,比较两组总生存,并行单变量和多变量分析。
主要发现
- 匹配后开放组与胸腔镜组3年总生存率相似(39.18% vs 44.33%,p=0.11)。
- y-pCR患者胸腔镜组3年生存率高于开放组(57.26% vs 65.19%,p=0.045)。
- y-pIII患者胸腔镜组3年生存率高于开放组(12.78% vs 22.31%,p=0.028)。
- y-pT0N+患者胸腔镜组3年生存率高于开放组(15.79% vs 41.01%,p=0.010)。
- 多变量分析中,手术方式仅在倾向评分匹配前为独立预后因素,匹配后不是独立预后因素。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The goal of this study was to investigate the overall survival between open and thoracoscopic oesophagectomy in patients with oesophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (NCRT). METHODS: The Taiwan Cancer Registry was queried for ESCC from 2008 to 2016. We enrolled 2250 patients with ESCC receiving NCRT plus open (n = 487) or thoracoscopic (n = 1763) oesophagectomy. One-to-two propensity score matching between open and thoracoscopic oesophagectomy was performed. Overall survival was compared between the 2 groups before and after propensity score matching. Univariable analysis and multivariable analysis were performed to identify prognostic factors. RESULTS: After one-to-two propensity score matching, 353 patients were in the open group and 706 patients were in the thoracoscopic group. The 3-year overall survival rates for matched patients treated with open or thoracoscopic oesophagectomy were similar (39.18% vs 44.33%, p = 0.11). Better overall survival was associated with thoracoscopic oesophagectomy for the patients in the y-pathological complete response stage (pCR) (57.26% vs 65.19%, p = 0.045), y-pathological III stage (12.78% vs 22.31%, p = 0.028) and y-pathological T0N+ stage (15.79% vs 41.01%, p = 0.010). In multivariable analysis, surgical approach was an independent prognostic factor only before propensity score matching. After matching, surgical approach was not an independent prognostic factor. CONCLUSIONS: This propensity-matched study demonstrated that open and thoracoscopic oesophagectomies are associated with similar long-term survival in patients with ESCC undergoing NCRT. Stage-specific comparisons showed that thoracoscopic oesophagectomy is associated with better survival than open oesophagectomy in patients with the pathological complete response, y-pathological III and y-pathological T0N+ stages and with similar survival in y-pathological I/II patients.
引用
- Chen HS, Lin CH, Wu SC, et al. Comparing survival between neoadjuvant chemoradiotherapy followed by open or thoracoscopic oesophagectomy in patients with oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 2022. PMID: 35303068. doi:10.1093/ejcts/ezac114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。